Your browser is no longer supported. Please, upgrade your browser.
Avid Bioservices, Inc.
Index- P/E228.04 EPS (ttm)0.09 Insider Own0.20% Shs Outstand61.14M Perf Week-0.38%
Market Cap1.24B Forward P/E61.71 EPS next Y0.34 Insider Trans-20.54% Shs Float60.48M Perf Month-13.20%
Income6.00M PEG15.20 EPS next Q0.03 Inst Own95.70% Short Float7.60% Perf Quarter-9.33%
Sales101.20M P/S12.21 EPS this Y120.80% Inst Trans10.50% Short Ratio7.64 Perf Half Y16.36%
Book/sh0.73 P/B28.74 EPS next Y45.92% ROA- Target Price28.25 Perf Year170.36%
Cash/sh2.71 P/C7.74 EPS next 5Y15.00% ROE- 52W Range6.89 - 28.36 Perf YTD81.80%
Dividend- P/FCF- EPS past 5Y31.60% ROI7.00% 52W High-26.02% Beta2.26
Dividend %- Quick Ratio2.90 Sales past 5Y16.70% Gross Margin31.80% 52W Low204.50% ATR1.35
Employees252 Current Ratio3.20 Sales Q/Q21.30% Oper. Margin- RSI (14)40.91 Volatility6.07% 5.06%
OptionableYes Debt/Eq0.00 EPS Q/Q55.30% Profit Margin- Rel Volume2.31 Prev Close20.14
ShortableYes LT Debt/Eq3.11 EarningsSep 08 AMC Payout- Avg Volume601.36K Price20.98
Recom1.70 SMA20-8.56% SMA50-14.56% SMA2006.68% Volume1,390,874 Change4.17%
Mar-17-21Initiated RBC Capital Mkts Outperform $21
Nov-10-20Initiated KeyBanc Capital Markets Overweight $12
Dec-10-19Upgrade First Analysis Sec Outperform → Strong Buy
Oct-17-19Initiated Stephens Overweight $8
Oct-16-19Initiated Craig Hallum Buy $11
Jun-28-19Upgrade Janney Neutral → Buy $10
May-09-19Downgrade Janney Buy → Neutral
Sep-14-21 10:00AM  
Sep-09-21 03:00PM  
Sep-08-21 04:05PM  
Sep-02-21 04:05PM  
Sep-01-21 04:05PM  
Aug-08-21 03:59AM  
Jul-29-21 12:19PM  
Jul-20-21 09:27AM  
Jul-01-21 08:05AM  
Jun-29-21 07:00PM  
Jun-24-21 02:05AM  
Jun-22-21 04:05PM  
Jun-04-21 04:36AM  
May-25-21 08:05AM  
May-21-21 09:55AM  
Apr-27-21 10:31AM  
Apr-25-21 04:20AM  
Apr-22-21 05:54PM  
Apr-15-21 04:05PM  
Apr-14-21 09:40AM  
Apr-07-21 08:29AM  
Apr-06-21 09:57AM  
Mar-23-21 09:24AM  
Mar-22-21 09:02AM  
Mar-17-21 08:05AM  
Mar-12-21 06:01AM  
Mar-10-21 12:20AM  
Mar-08-21 07:00PM  
Mar-03-21 04:05PM  
Mar-01-21 04:05PM  
Feb-23-21 11:57PM  
Feb-22-21 08:05AM  
Feb-18-21 01:08PM  
Feb-03-21 07:00AM  
Jan-26-21 11:21AM  
Jan-10-21 01:55AM  
Dec-15-20 08:51PM  
Dec-14-20 04:05PM  
Dec-10-20 09:00AM  
Dec-09-20 04:45PM  
Dec-07-20 04:05PM  
Dec-05-20 01:36AM  
Dec-03-20 11:03AM  
Dec-02-20 09:30PM  
Dec-01-20 04:05PM  
Nov-24-20 04:05PM  
Nov-08-20 08:20AM  
Nov-05-20 10:00AM  
Sep-24-20 09:29AM  
Sep-15-20 04:05PM  
Sep-10-20 10:29AM  
Sep-03-20 07:55AM  
Sep-02-20 07:25AM  
Sep-01-20 06:30PM  
Aug-31-20 04:05PM  
Aug-26-20 08:05AM  
Aug-25-20 04:05PM  
Aug-20-20 08:30AM  
Aug-19-20 11:27AM  
Aug-10-20 09:56AM  
Aug-06-20 08:05AM  
Jul-28-20 08:05AM  
Jul-05-20 06:34PM  
Jul-03-20 12:13PM  
Jul-02-20 01:11PM  
Jul-01-20 08:30AM  
Jun-30-20 11:36PM  
Jun-23-20 04:05PM  
Jun-18-20 12:30PM  
Jun-03-20 04:05PM  
May-06-20 08:05AM  
May-02-20 08:31AM  
Apr-13-20 08:05AM  
Mar-26-20 08:05AM  
Mar-18-20 06:23AM  
Mar-12-20 10:07AM  
Mar-10-20 05:25PM  
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Green Nicholas StewartPresident & CEOAug 02Sale25.5618,701477,99819,852Aug 03 08:17 PM
Ziebell Mark RV. P., General CounselJul 12Sale25.617,207184,57413,911Jul 13 09:40 PM
Hart Daniel RChief Financial OfficerJul 12Sale25.615,409138,52826,103Jul 13 09:39 PM
Bamforth Mark RDirectorMar 17Buy18.18126,0002,290,680126,000Mar 19 05:25 PM
Bamforth Mark RDirectorMar 17Sale18.1826,000472,6800Mar 19 05:25 PM
Bamforth Mark RDirectorMar 17Sale18.18100,0001,818,0000Mar 19 05:25 PM